-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chronic hepatitis C virus (HCV) infection is associated with an increased risk of chronic kidney disease (CKD)
Infection immune blood vessel
If chronic HCV infection is not treated, the survival and quality of life of patients with severe renal impairment will be greatly affected
The emergence of direct-acting antiviral drugs (DAAs) without interferon (IFN) has transformed the treatment mode of HCV because of its high sustained virological response (SVR) rate and excellent patient tolerance.
At present, regarding the effects of sofosbuvir/velpatasvir (sofosbuvir/velpatasvir, SOF/VEL) combined or not combined with low-dose ribavirin (RBV) on chronic hepatitis C virus (HCV) infection and severe renal damage ( RI) Patients have limited real-world effectiveness and safety data
The performance of SOF/VEL with or without low-dose RBV in patients with chronic kidney disease stage 4 or 5 HCV infection SOF/VEL with or without the performance of low-dose RBV in patients with chronic kidney disease stage 4 or 5 HCV infection
In this trial, 191 patients with liver disease in the compensatory phase (n=181) and decompensated phase (n=10) received SOF/VEL alone (400/100mg/day) or SOF/VEL and low-dose RBV ( 200mg/day) treatment for 12 weeks and retrospective recruitment in 15 academic centers in Taiwan
12
Experimental design flow chart
Experimental design flow chart Experimental design flow chartThe results showed that the SVR 12 rate of EP and PP analysis was 94.
12 In patients with compensated liver disease, through EP and PP analysis, SVR 12 rates were 95.
Among the 20 serious adverse events (AEs), none was judged to be related to SOF/VEL or RBV.
SOF/VEL combined or not combined with low-dose RBV is effective and well tolerated in patients with severe RI infected by HCV SOF/VEL combined or not combined with low-dose RBV is effective and well tolerated in patients with severe RI infected by HCV
Original source:
Original source:Chen-Hua Liu et al.
Chen-Hua Liu et al.
Leave a message here